Posted inGenetics
Midlife Brain Aging Linked to Immune Cell Remodeling, Blood-Brain Barrier Decline
Credit: koto_feja / Getty Images New data from a National Institutes of Health-funded study shows that midlife, the immune cell…
Posted inGenetics
Turning Solar Power Into Protein
Credit: TUM Campus Straubing for Biotechnology and Sustainability According to projections from the United Nations, global food demand could increase…
Posted inBiotechnology
Chutes & Ladders—Biogen R&D vet gets in Formation
AI-focused Formation Bio has found a new chief scientist with extensive experience in biotech, Big Pharma and academia. Michael Ehlers,…
Posted inBiotechnology
From Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotech
Whether it's looming tariff threats or the rise of China, you need a truly global view to navigate today's biopharma…
Posted inGenetics
Samsung Proposes Offer to Acquire Swiss CDMO Specializing in Peptides
Samsung Biologics CEO, John Rim, says the PolyPeptide acquisition reinforces the company’s long-term growth strategy by not only broadening its…
Posted inBiotechnology
Scancell to go public after winning reverse merger bid for troubled Neuphoria
Scancell and Neuphoria have made their union official via a reverse merger that will result in a Nasdaq listing for…
Posted inBiotechnology
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
Eli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the…
Posted inMedical Technology
Roche Diagnostics growth remains muted amid China headwinds
Roche’s Diagnostics division continues to battle growth headwinds, notching a 3% increase in sales.
Posted inBiotechnology
Australian biopharma Clinuvel to shed up to 20% of workforce in move to US
Australian biopharma Clinuvel Pharmaceuticals is moving its headquarters to the U.S.— but up to a fifth of the company’s workforce…
Posted inBiotechnology
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
Roche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told…